“Rhymin’ G pants are Nerd tech?”
ri ME je pant / NUR tek
Released in 2020
$900 - $1,300 / mo
❖ Calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant")
❖ FDA approved for acute treatment of migraine headaches
Rimegepant (Nurtec ODT) is the second small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist ("gepant") to be FDA-approved for acute treatment of migraine. Ubrogepant (Ubrelvy) was the first.
Rimegepant resolved headache pain at 2 hours post-dose in 20-21% of patients, compared to 11-12% with placebo. It appears to be similarly effective as ubrogepant.
Unlike triptans, CGRP receptor antagonists can be used in patients with vascular disease.
Nausea is the most common adverse effect in clinical trials.
Rimegepant should not be taken with strong CYP3A4 inhibitors, strong or moderate CYP3A4 inducers, or inhibitors of P-gp or BCRP.
Learn about the fish and other interaction mnemonics in Cafer's Psychopharmacology - Visualize to Memorize 270 Medication Mascots